IDH1 and central nervous system cancer: Accordingly, the Food and Drug Administration (FDA) has approved the mutant IDH1 inhibitor, ivosidenib [155], and IDH2 inhibitor, enasidenib [156] for adults with relapsed or refractory acute myeloid leukemia, inhibitors of mutant IDH have entered clinical trials for glioma treatment [157,158].